Items where Author is "Meyer-Rath, G"
Up a level |
Jump to: Article | Conference or Workshop Item
Number of items: 13.
Article
Kranzer, K;
Lawn, SD;
Meyer-Rath, G;
Vassall, A;
Raditlhalo, E;
Govindasamy, D;
van Schaik, N;
Wood, R;
Bekker, LG;
(2012)
Feasibility, Yield, and Cost of Active Tuberculosis Case Finding Linked to a Mobile HIV Service in Cape Town, South Africa: A Cross-sectional Study.
PLoS medicine, 9 (8).
e1001281.
ISSN 1549-1277
DOI: https://doi.org/10.1371/journal.pmed.1001281
McCarthy, K;
Chersich, MF;
Vearey, J;
Meyer-Rath, G;
Jaffer, A;
Simpwalo, S;
Venter, WDF;
(2009)
Good treatment outcomes among foreigners receiving antiretroviral therapy in Johannesburg, South Africa.
International journal of STD & AIDS, 20 (12).
pp. 858-862.
ISSN 0956-4624
DOI: https://doi.org/10.1258/ijsa.2009.009258
Full text not available from this repository.
Meyer-Rath, G;
(2007)
The cost-effectiveness of HIV control: Getting the priorities right.
Southern African journal of HIV medicine (27).
pp. 15-16.
ISSN 1608-9693
DOI: https://doi.org/10.4102/sajhivmed.v8i2.621
Meyer-Rath, G;
Miners, A;
Santos, AC;
Variava, E;
Venter, WD;
(2012)
Cost and resource use of patients on antiretroviral therapy in the urban and semi-urban public sectors of South Africa.
Journal of acquired immune deficiency syndromes (1999), 61 (3).
e25-32.
ISSN 1525-4135
DOI: https://doi.org/10.1097/QAI.0b013e31826cc575
Full text not available from this repository.
Meyer-Rath, G;
Pienaar, J;
Brink, B;
van Zyl, A;
Muirhead, D;
Grant, A;
Churchyard, G;
Watts, C;
Vickerman, P;
(2015)
The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis.
PLoS medicine, 12 (9).
e1001869.
ISSN 1549-1277
DOI: https://doi.org/10.1371/journal.pmed.1001869
Meyer-Rath, G;
Richter, M;
(2007)
User fees, transport costs, and the ethics of exemption: How free is free ART?
Southern African journal of HIV medicine (27).
52-+.
ISSN 1608-9693
http://researchonline.lshtm.ac.uk/id/eprint/8592
Renaud, A;
Basenya, O;
de Borman, N;
Greindl, I;
Meyer-Rath, G;
(2009)
The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi.
AIDS care, 21 (11).
pp. 1388-1394.
ISSN 0954-0121
DOI: https://doi.org/10.1080/09540120902884042
Full text not available from this repository.
Terris-Prestholt, F;
Foss, AM;
Cox, AP;
Heise, L;
Meyer-Rath, G;
Delany-Moretlwe, S;
Mertenskoetter, T;
Rees, H;
Vickerman, P;
Watts, CH;
(2014)
Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.
BMC infectious diseases, 14 (1).
p. 14.
ISSN 1471-2334
DOI: https://doi.org/10.1186/1471-2334-14-14
Vickerman, P;
Devine, A;
Foss, AM;
Delany-Moretlwe, S;
Mayaud, P;
Meyer-Rath, G;
(2011)
The Cost-Effectiveness of Herpes Simplex Virus-2 Suppressive Therapy With Daily Aciclovir for Delaying HIV Disease Progression Among HIV-1-Infected Women in South Africa.
Sexually transmitted diseases, 38 (5).
pp. 401-9.
ISSN 0148-5717
DOI: https://doi.org/10.1097/OLQ.0b013e31820b8bc8
Full text not available from this repository.
Conference or Workshop Item
Devine, A;
Meyer-Rath, G;
Foss, A;
Vickerman, P;
Edwards, M;
Bachmann, M;
Mayaud, P;
Delany-Moretlwe, S;
(2009)
Cost and cost effectiveness of Herpes simplex virus-type 2 (hsv-2) suppressive therapy in HIV-1 and HSV-2 infected women in Johannesburg, South Africa.
[Conference or Workshop Item]
http://researchonline.lshtm.ac.uk/id/eprint/5470
Full text not available from this repository.
Foss, AM;
Terris-Prestholt, F;
Cox, AP;
Heise, L;
Meyer-Rath, G;
Delany-Moretlwe, S;
Mertenskoetter, T;
Rees, H;
Vickerman, P;
Watts, CH;
(2012)
Model projections of the population-level impact, on HIV and herpes simplex virus type-2 (HSV-2), and cost-effectiveness of tenofovir gel, an antiretroviral microbicide.
[Conference or Workshop Item]
http://researchonline.lshtm.ac.uk/id/eprint/20873
Full text not available from this repository.
Vickerman, P;
Devine, A;
Foss, A;
Delany-Moretlwe, S;
Mayaud, P;
Meyer-Rath, G;
(2012)
Could HSV-2 suppressive therapy using valacyclovir be a cost-effective strategy for reducing HIV disease progression and transmission among HIV-1 infected women in South Africa?
[Conference or Workshop Item]
http://researchonline.lshtm.ac.uk/id/eprint/20895
Full text not available from this repository.
Vickerman, P;
Devine, A;
Meyer-Rath, G;
Foss, A;
Delany-Moretlwe, S;
Mayaud, P;
(2009)
Modelling the cost-effectiveness of HSV-2 suppressive therapy for reducing HIV progression and infectivity among HIV infected women in South Africa.
[Conference or Workshop Item]
http://researchonline.lshtm.ac.uk/id/eprint/5471
Full text not available from this repository.